Tranzyme Pharma
Investor Relations Department
5001 South Miami Boulevard
Suite 300
Durham, NC 27703
United States

Visit IR website
Sign-up for email alerts

NASDAQ: TZYM [1]	
Last Trade:	0.59
Trade Time:	12:30 PM ET May 21, 2013
Change:	-0.01 (0.840%)
Day Range	0.59 - 0.61
52-Week Range	0.40 - 5.16
Volume	112,100
Market Cap. ($M)	16.284
Shares Out (M)	27.600

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzyme's product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH™, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner.... (more)

Stock Performance

Press Releases [View all]

May 9, 2013
Tranzyme Pharma Announces First Quarter 2013 Financial Results

May 2, 2013
Tranzyme Pharma to Report First Quarter 2013 Financial Results

Apr 23, 2013
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement

Mar 28, 2013
Tranzyme Pharma Announces Fourth Quarter and Full-Year 2012 Financial Results

Mar 13, 2013
Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Third Quarter Financial Results

Mar 28, 2013
Annual Report (10-K)

May 14, 2013
Quarterly Report (10-Q)

Nov 9, 2012
Quarterly Report (10-Q)

Aug 10, 2012
Quarterly Report (10-Q)

NASDAQ OMX